AstraZeneca's shares have proved to be a roller coaster as evidenced by its surge and slump in the markets. Only recently it leapt on the back of stellar first-quarter forecasts and experienced a tumble despite posting
strong sales for its cancer drug. The company is grappling with wavering demand for its COVID-19 vaccines, leading to a hurt in the revenue and a subsequent drop in the stock value. On a positive note, the company is promising a 2024 growth target. It commands an impressive
85% ownership, indicating strong institutional backing. Despite weaker-than-expected quarterly reports, AstraZeneca is betting big on its cancer pipeline to power future gains. Other significant moves include its acquisition of
Amolyt Pharma and
Icosavax – both geared towards expanding its rare disease portfolio. Another notable venture is its next-generation cancer therapy collaboration with
Fusion, with a deal valued at $2bn. The stock seems attractive to investors, even with a few hiccups such as the company's vaccine causing
rare cases of blood clotting.
AstraZeneca Stocks News Analytics from Mon, 11 Sep 2023 07:00:00 GMT to Thu, 09 May 2024 07:00:00 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor -3
